Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Japan Approves Taisho’s Visceral Fat-Reducing Med as Nonprescription Drug
Taisho Pharmaceutical said on February 17 that its nonprescription drug containing orlistat has been approved in Japan for the reduction of visceral fat. The agent, known as Alli overseas, will be sold as a “behind-the-counter” med requiring face-to-face guidance by…
To read the full story
Related Article
- Taisho’s Nonprescription Anti-Obesity Drug to Hit Pharmacy Shelves on April 8
March 6, 2024
- Taisho Aims to Make “Alli” 5th Leg of Its Consumer Healthcare Biz, Eyes Annual Sales of 2-3 Billion Yen
December 15, 2023
- Nonprescription Obesity Med Unlikely to Hit Japan Market Until Next Year
May 17, 2023
- Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
November 29, 2022
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…